HomeCompareCSML vs ABBV

CSML vs ABBV: Dividend Comparison 2026

CSML yields 0.37% · ABBV yields 3.12%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ABBV wins by $84.5K in total portfolio value
10 years
CSML
CSML
● Live price
0.37%
Share price
$34.95
Annual div
$0.13
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.2K
Annual income
$38.32
Full CSML calculator →
ABBV
AbbVie Inc.
● Live price
3.12%
Share price
$213.22
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$104.7K
Annual income
$25,725.73
Full ABBV calculator →

Portfolio growth — CSML vs ABBV

📍 ABBV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCSMLABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CSML + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CSML pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CSML
Annual income on $10K today (after 15% tax)
$31.79/yr
After 10yr DRIP, annual income (after tax)
$32.57/yr
ABBV
Annual income on $10K today (after 15% tax)
$265.10/yr
After 10yr DRIP, annual income (after tax)
$21,866.87/yr
At 15% tax rate, ABBV beats the other by $21,834.30/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CSML + ABBV for your $10,000?

CSML: 50%ABBV: 50%
100% ABBV50/50100% CSML
Portfolio after 10yr
$62.5K
Annual income
$12,882.02/yr
Blended yield
20.63%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

CSML
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+20.1% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CSML buys
0
ABBV buys
0
No recent congressional trades found for CSML or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCSMLABBV
Forward yield0.37%3.12%
Annual dividend / share$0.13$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$20.2K$104.7K
Annual income after 10y$38.32$25,725.73
Total dividends collected$379.00$63.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: CSML vs ABBV ($10,000, DRIP)

YearCSML PortfolioCSML Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$10,737$37.40$11,559$438.51$822.00ABBV
2$11,527$37.53$13,494$640.86$2.0KABBV
3$12,371$37.65$15,951$945.97$3.6KABBV
4$13,275$37.77$19,152$1,413.89$5.9KABBV
5$14,242$37.87$23,443$2,146.38$9.2KABBV
6$15,277$37.97$29,391$3,321.96$14.1KABBV
7$16,384$38.07$37,948$5,265.87$21.6KABBV
8$17,569$38.16$50,795$8,596.74$33.2KABBV
9$18,837$38.24$71,034$14,549.41$52.2KABBV
10$20,194$38.32$104,715$25,725.73$84.5KABBV

CSML vs ABBV: Complete Analysis 2026

CSMLStock

The fund invests at least 80% of the value of its assets (net assets plus the amount of any borrowings for investment purposes) in securities of small-capitalization U.S. issuers. The underlying index applies the Chaikin Power Gauge, a quantitative multi-factor model that seeks to identify securities that are expected to outperform peers, to select securities from the Nasdaq US 1500 Index.

Full CSML Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this CSML vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CSML vs SCHDCSML vs JEPICSML vs OCSML vs KOCSML vs MAINCSML vs JNJCSML vs MRKCSML vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.